Sign In
Buy ALNY
$216.98
-2.22 (-1.01%)
At Close: Aug 10, 2026
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
11:16am, Monday, 08'th Sep 2025
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript
04:58pm, Wednesday, 03'rd Sep 2025
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Citi's Biopharma Back to School Conference September 3, 2025 1:45 PM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Kevin Fitzgerald - Execu
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives
12:56am, Wednesday, 03'rd Sep 2025
Alnylam's strong clinical productivity and commercial execution continue to support my view that it's one of the best all-around biotechs, with a robust revenue and earnings outlook. Amvuttra's TTR-CM
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
11:51am, Monday, 01'st Sep 2025
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUT
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
10:30am, Saturday, 30'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT)
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
10:30am, Saturday, 30'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardio
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
11:11am, Thursday, 28'th Aug 2025
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
mRNA Biotechs - Long-Term Value Risks Abound
06:20am, Thursday, 28'th Aug 2025
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c
Scenic Enters License and Research Agreement with Alnylam
05:00am, Tuesday, 26'th Aug 2025
Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
08:00am, Tuesday, 05'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?
01:21pm, Monday, 04'th Aug 2025
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
02:28pm, Friday, 01'st Aug 2025
Alnylam Pharmaceuticals Inc. ALNY reported upbeat second-quarter earnings and 2025 guidance on Thursday.
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
12:51pm, Friday, 01'st Aug 2025
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
